REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
17 hedge funds and large institutions have $1.65M invested in REVIVA PHARMA HLDGS INC in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
136% more call options, than puts
Call options by funds: $704K | Put options by funds: $298K
42% more funds holding
Funds holding: 12 → 17 (+5)
0.39% less ownership
Funds ownership: 0.62% → 0.23% (-0.39%)
20% less capital invested
Capital invested by funds: $2.05M → $1.65M (-$402K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$116K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$99.8K |
| 3 |
VF
Virtu Financial
New York
|
+$63.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$55.6K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$41.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.32M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$80.7K |
| 3 |
Renaissance Technologies
New York
|
-$20K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.62K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$3.59K |
RVPH Hedge Fund Activity: Q3 2022 in Review
17 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q3 2022, worth a combined $1.65M — down 20% from $2.05M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new RVPH positions and 2 closed out — a net gain of 5 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $116K. The largest seller was Tang Capital Management, exiting entirely with an estimated $1.32M sold.
- 17 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q3 2022, up from 12 in Q2 2022.
- Funds reported $1.65M of REVIVA PHARMA HLDGS INC stock for Q3 2022, down 20% quarter-over-quarter.
- 7 funds opened new REVIVA PHARMA HLDGS INC positions in Q3 2022 and 2 closed out, a net change of +5 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q3 2022 was BlackRock, an estimated $116K added.
- The largest REVIVA PHARMA HLDGS INC seller in Q3 2022 was Tang Capital Management, an estimated $1.32M sold.
Based on aggregated 13F filings for Q3 2022.